XRAY DENTSPLY SIRONA Inc.

Investors can certainly boost their returns by concentrating on stocks trading between $1 and $10. However, a disciplined approach is necessary because many of these businesses are speculative and lack the underlying fundamentals to support their prices.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how dental equipment & technology stocks fared in Q2, starting with Dentsply Sirona (NASDAQ:XRAY).

Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built their fortunes by purchasing wonderful businesses at reasonable prices. But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.

XRAY's digital dentistry, R&D and restructuring support growth, but CAD/CAM, implants, SureSmile and tariff pressures pose near-term risks.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.

XRAY beat Q2 earnings and revenue estimates, held 2026 guidance and improved cash flow, but falling sales and margin pressure cloud the recovery.

DENTSPLY SIRONA (XRAY) shares are in focus after the company reported second quarter 2026 results that returned the business to profitability while net sales declined 4.1% year over year. The latest results and upcoming appearance at the Baird 2026 Global Healthcare Conference come after a mixed share price pattern for DENTSPLY SIRONA, with a 7 day share price return of 3.53% but a 30 day share price return that declined 19.90%. Recent momentum has been choppy, as a 90 day share price return...

DENTSPLY SIRONA stock has had a difficult run over the past few years, yet on broad valuation checks it now screens as one of the cheaper options in its peer group. The share price history and the current multiples are sending very different signals about what the market expects from the business. Over the past 5 years, DENTSPLY SIRONA shareholders have seen the stock fall about 79.6%, which points to a long period of weak sentiment that still weighs on expectations today. The valuation...

Dentsply Sirona recently reported second-quarter 2026 results showing a 4.1% year-over-year net sales decline but a return to net income, with higher margins and stronger cash generation, and also confirmed it will present at the Baird 2026 Global Healthcare Conference on September 15, 2026. The combination of improved profitability and cash flow, despite weaker revenue and a history of pressure on returns, led management to reiterate full-year 2026 guidance, highlighting a sharper focus on...

On August 6, Dentsply Sirona (NASDAQ:XRAY) reported second-quarter 2026 results that pulled the stock in two directions at once. Net sales fell 4.1% year over year to $898 million, yet the company swung from a $45 million net loss a year earlier to $37 million in net income, with diluted earnings per share of $0.18 […]

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 25.1% over the past six months, topping the S&P 500 by 13.1 percentage points.

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some may still have unproven business models, leaving them vulnerable to the ebbs and flows of the broader market.

Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.

Henry Schein's stronger Q2 sales and margins prompt a 2026 outlook hike, but second-half savings execution remains key to sustaining earnings momentum.

Align's $37.5M U.K. VAT liability, new 20% VAT charges and pending appeal add fresh earnings uncertainty amid currency and mix pressures.

Dentsply Sirona’s second quarter results were met with a negative market reaction, as shares declined following revenue and non-GAAP earnings that exceeded Wall Street expectations. Management attributed the year-on-year revenue decline primarily to lower sales volumes in key product segments and regions, especially in the Americas and EMEA, and highlighted ongoing challenges in capital equipment demand and inventory reduction by distributor partners. CEO Daniel Scavilla described the company’s

Revenue declined 4.1% as restructuring efforts begin to take hold.

Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak full-year revenue forecast.

DENTSPLY SIRONA (NASDAQ:XRAY) reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europ

Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year net sales guidance and an update on long running share repurchases. The company reported quarterly sales of US$898 million compared with US$936 million a year earlier. Net income for the quarter was US$37 million compared with a net loss of US$45 million in the prior year period, with basic and diluted earnings per share from...

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Moby summary of DENTSPLY SIRONA Inc.'s Q2 2026 earnings call

Dentsply (XRAY) delivered earnings and revenue surprises of +44.44% and +1.60%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dental products company Dentsply Sirona (NASDAQ:XRAY) reported Q2 CY2026 results topping the market’s revenue expectations, but sales fell by 4.1% year on year to $898 million. On the other hand, the company’s full-year revenue guidance of $3.55 billion at the midpoint came in 1% below analysts’ estimates. Its non-GAAP profit of $0.52 per share was 50.1% above analysts’ consensus estimates.

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

Ariel Investments, an investment management company, released its “Ariel Focus Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund returned 2.14% in the second quarter of 2026, underperforming the Russell 1000 Value and S&P 500, which gained 13.87% and 15.20%, respectively. The fund benefited from gains in several […]

Dentsply Sirona has been treading water for the past six months, recording a small loss of 0.5% while holding steady at $12.66. The stock also fell short of the S&P 500’s 7.9% gain during that period.